Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”

New treatment options especially of solid tumors including for metastasized prostate cancer (PCa) are urgently needed. Recent treatments of leukemias with chimeric antigen receptors (CARs) underline their impressive therapeutic potential. However CARs currently applied in the clinics cannot be repea...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Feldmann, Anja, Arndt, Claudia, Bergmann, Ralf, Loff, Simon, Cartellieri, Marc, Bachmann, Dominik, Aliperta, Roberta, Hetzenecker, Mirjam, Ludwig, Florian, Albert, Susann, Ziller-Walter, Pauline, Kegler, Alexandra, Koristka, Stefanie, Gärtner, Sebastian, Schmitz, Marc, Ehninger, Armin, Ehninger, Gerhard, Pietzsch, Jens, Steinbach, Jörg, Bachmann, Michael
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2017
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5458214/
https://ncbi.nlm.nih.gov/pubmed/28404896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15572
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg